Skip to main content
Journal cover image

A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).

Publication ,  Journal Article
Infante, JR; Ramanathan, RK; George, D; Tan, E; Quinlan, M; Liu, A; Scott, JW; Sharma, S
Published in: Cancer Chemother Pharmacol
April 2015

PURPOSE: This 2-arm crossover study compared the relative bioavailability of two dovitinib (TKI258) formulations [anhydrate clinical service form (CSF) capsule and monohydrate final market image (FMI) tablet; Arm 1] and determined the effect of food on dovitinib exposure (Arm 2). METHODS: Patients with advanced solid tumors, excluding breast cancer, were enrolled in 1 of the 2 arms of the study. Patients in Arm 1 were randomized to a single 500-mg dose of CSF capsule or FMI tablet followed by 7 days of rest and 500 mg of the other formulation. Patients in Arm 2 received 300 mg of FMI tablet daily and were randomized to follow 1 of 6 meal sequences, each with 3 prandial conditions: low fat (LF), high fat (HF), or no meal (NM). RESULTS: In Arm 1 (n = 21), 17 patients were evaluable. FMI tablet compared with CSF capsule showed only slight reductions in the adjusted geometric means for area under the plasma concentration-time curve (AUClast; 3%) and maximum plasma concentration (C max; 1%). In Arm 2 (n = 42), 19 patients were evaluable. HF meal versus NM showed a 9% decrease in the adjusted geometric mean for AUClast and an 18% decrease for C max. Comparison of LF meal versus NM showed a 1% decrease for AUClast and a 10% decrease for C max. Common adverse events suspected to be study drug related included vomiting, diarrhea, nausea, and fatigue. CONCLUSIONS: Dovitinib FMI tablet had similar systemic exposure to the CSF capsule and was not affected by food.

Duke Scholars

Published In

Cancer Chemother Pharmacol

DOI

EISSN

1432-0843

Publication Date

April 2015

Volume

75

Issue

4

Start / End Page

729 / 737

Location

Germany

Related Subject Headings

  • Tablets
  • Quinolones
  • Protein-Tyrosine Kinases
  • Oncology & Carcinogenesis
  • Neoplasms
  • Middle Aged
  • Male
  • Humans
  • Food-Drug Interactions
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Infante, J. R., Ramanathan, R. K., George, D., Tan, E., Quinlan, M., Liu, A., … Sharma, S. (2015). A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258). Cancer Chemother Pharmacol, 75(4), 729–737. https://doi.org/10.1007/s00280-015-2681-3
Infante, Jeffrey R., Ramesh K. Ramanathan, Daniel George, Eugene Tan, Michelle Quinlan, Angela Liu, Jeffrey W. Scott, and Sunil Sharma. “A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).Cancer Chemother Pharmacol 75, no. 4 (April 2015): 729–37. https://doi.org/10.1007/s00280-015-2681-3.
Infante JR, Ramanathan RK, George D, Tan E, Quinlan M, Liu A, et al. A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258). Cancer Chemother Pharmacol. 2015 Apr;75(4):729–37.
Infante, Jeffrey R., et al. “A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).Cancer Chemother Pharmacol, vol. 75, no. 4, Apr. 2015, pp. 729–37. Pubmed, doi:10.1007/s00280-015-2681-3.
Infante JR, Ramanathan RK, George D, Tan E, Quinlan M, Liu A, Scott JW, Sharma S. A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258). Cancer Chemother Pharmacol. 2015 Apr;75(4):729–737.
Journal cover image

Published In

Cancer Chemother Pharmacol

DOI

EISSN

1432-0843

Publication Date

April 2015

Volume

75

Issue

4

Start / End Page

729 / 737

Location

Germany

Related Subject Headings

  • Tablets
  • Quinolones
  • Protein-Tyrosine Kinases
  • Oncology & Carcinogenesis
  • Neoplasms
  • Middle Aged
  • Male
  • Humans
  • Food-Drug Interactions
  • Female